본문으로 건너뛰기
← 뒤로

A Rare Case of De Novo Acute Myeloid Leukemia, Featuring a () Amplification.

증례보고 1/5 보강
Diagnostics (Basel, Switzerland) 📖 저널 OA 100% 2021: 4/4 OA 2022: 16/16 OA 2023: 20/20 OA 2024: 45/45 OA 2025: 135/135 OA 2026: 136/136 OA 2021~2026 2026 Vol.16(6)
Retraction 확인
출처

Hassan F, Chen J, Westphal C, Tirado CA

📝 환자 설명용 한 줄

We present a case of a patient in their 80s initially presenting with myelodysplastic syndromes (MDS).

이 논문을 인용하기

↓ .bib ↓ .ris
APA Hassan F, Chen J, et al. (2026). A Rare Case of De Novo Acute Myeloid Leukemia, Featuring a () Amplification.. Diagnostics (Basel, Switzerland), 16(6). https://doi.org/10.3390/diagnostics16060820
MLA Hassan F, et al.. "A Rare Case of De Novo Acute Myeloid Leukemia, Featuring a () Amplification.." Diagnostics (Basel, Switzerland), vol. 16, no. 6, 2026.
PMID 41897553 ↗

Abstract

We present a case of a patient in their 80s initially presenting with myelodysplastic syndromes (MDS). Chromosomal analysis showed an abnormal female karyotype with a complex karyotype. Metaphase FISH confirmed four copies of in 24.5% [49/200] and amplification of () with more than four copies in 22% [44/200]. FISH also revealed the presence of (8q24) on the long arm of chromosome 2 at 2q33 locus, two copies of on each homolog 22, and two additional copies of on a derivative chromosome 22. Flow cytometric analysis revealed a population of aberrant myeloid blasts (15-17%). Bone marrow analysis showed hypercellular marrow with a significant increase in myeloid blasts (~50%) and trilineage dysplasia. Eventually, these findings were consistent with a final diagnosis of acute myeloid leukemia non-M3 and a complex karyotype, correlating with cytogenetics, flow cytometry, molecular, and clinical findings. The patient's clinical course was marked by a rapid deterioration, including recurrent arrhythmias, hypoxic respiratory failure, and septic shock. Given their poor clinical status and adverse-risk molecular profile, care was transported to hospice. The presence of amplification is a rare event in AML and is present in ~1% of AML and MDS cases. translocation, () amplification, and 5q/20q losses suggest secondary therapy-related AML and categorize this case in the adverse risk prognosis under the ELN 2022 guidelines.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기